Older melanoma patients may respond to anti-PD1 immunotherapy better than younger patients

(American Association for Cancer Research) With each decade of life, the likelihood of progression of melanoma after treatment with anti-PD1 immunotherapy decreased by 13 percent.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news